Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry


Kabasakal L., Toklu T., Yeyin N., Demirci E., Abuqbeitah M., Ocak M., ...More

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.26, no.2, pp.62-68, 2017 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.4274/mirt.08760
  • Journal Name: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.62-68
  • Keywords: PSMA, prostate-specific membrane antigen, Lu-177-PSMA, prostate cancer, castration-resistant prostate cancer, radionuclide therapy, SALIVARY-GLAND FUNCTION, PSMA INHIBITOR, PRECLINICAL EVALUATION, LIGAND, EXPRESSION, RADIATION, TISSUES
  • Istanbul University Affiliated: Yes

Abstract

Objective: The aim of the study was to estimate the radiation-absorbed doses and to study the in vivo and in vitro stability as well as pharmacokinetic characteristics of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA)-617.